Literature DB >> 30009490

Evaluation of the efficacy of transdermal drug delivery of calcipotriol plus betamethasone versus tacrolimus in the treatment of vitiligo.

Zeinab A Ibrahim1, Ghada F Hassan1, Hoda Y Elgendy2, Hanan A Al-Shenawy3.   

Abstract

BACKGROUND: Vitiligo is a common pigmentary disorder affecting about 1% of the general population. There are numerous medical and surgical treatments. Microneedling is an evolving treatment technique for an expanding number of dermatologic conditions. It is used also to augment transdermal drug delivery through pores created in the stratum corneum. AIM: To evaluate the efficacy of microneedling with tacrolimus versus its efficacy with calcipotriol plus betamethasone in vitiligo treatment.
METHODS: Twenty-five patients having vitiligo were selected and their symmetrical patches were divided into side A (right side) which received microneedling with dermapen and topical calcipotriol plus betamethasone and side B (left side) which received microneedling and topical tacrolimus. Every patient received a session every 2 weeks for a maximum 6 months (12 sessions) and follow-up for 3 months. Skin biopsies were taken before and after the treatment to evaluate the clinical results.
RESULTS: On side A, 60% of the patients showed excellent improvement while 32% showed excellent response on side B. The mean percentage of improvement was significantly higher on side A than side B (P = 0.017* ). It was effective in the most resistant sites of vitiligo such as: elbows, knees, extremities, and acral area. Histopathological examination showed a significant expression of HMB45 on side A more than side B (P = 0.005* ).
CONCLUSION: The combination of microneedling with calcipotriol plus betamethasone is more effective than its combination with tacrolimus. They are both effective in resistant sites. Both methods are safe, cheap, and good tolerated office techniques with minimal side effects.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  calcipotriol plus betamethasone; drug delivery; tacrolimus; treatment; vitiligo

Year:  2018        PMID: 30009490     DOI: 10.1111/jocd.12704

Source DB:  PubMed          Journal:  J Cosmet Dermatol        ISSN: 1473-2130            Impact factor:   2.696


  4 in total

Review 1.  Vitamin D and alopecia areata: possible roles in pathogenesis and potential implications for therapy.

Authors:  Xiran Lin; Xianmin Meng; Zhiqi Song
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

2.  Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial.

Authors:  Fariba Iraji; Ali Asilian; Zahra Talebzadeh; Mina Saber; Fatemeh Mokhtari; Amirhossein Siadat; Seyed Mohsen Hosseini
Journal:  Dermatol Res Pract       Date:  2021-11-30

Review 3.  Updates and new medical treatments for vitiligo (Review).

Authors:  David Emmanuel Kubelis-López; Natalia Aranza Zapata-Salazar; Salvador Luis Said-Fernández; Celia Nohemí Sánchez-Domínguez; Mauricio Andrés Salinas-Santander; Herminia Guadalupe Martínez-Rodríguez; Osvaldo Tomás Vázquez-Martínez; Uwe Wollina; Torello Lotti; Jorge Ocampo-Candiani
Journal:  Exp Ther Med       Date:  2021-05-25       Impact factor: 2.447

4.  CXCL9 as a key biomarker of vitiligo activity and prediction of the success of cultured melanocyte transplantation.

Authors:  Fuquan Lin; Wenting Hu; Wen Xu; Miaoni Zhou; Ai-E Xu
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.